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ABSTRACT
Mechanisms of Synthetic Cannabinoids on Cardiovascular Health
Madeleine A. Nelson
Thesis Director: Douglas S. Martin, Ph.D.

Cannabinoids encompass natural cannabis and synthetic cannabinoids. While the
synthetic cannabinoids interact with the same endogenous system as cannabis, their
effects are quite different and poorly understood. In addition to psychological effects that
trigger their use, these substances are linked to cardiovascular morbidity. To assess the
cardiovascular effect of synthetic cannabinoids, we first tested the hypothesis that
intravenous administration of a synthetic cannabinoid would increase blood pressure in
conscious rats. Second, we tested the hypothesis that the sympathetic nervous system is
involved by injecting a ganglion blocker to see if the cardiovascular response from
synthetic cannabinoids would be blocked. Third, we tested the hypothesis that the
hypothalamic paraventricular nucleus is involved by doing immunohistochemistry to
check for cFos fluorescence.
We found that synthetic cannabinoid use peaked with 7,000 calls to poison
control centers in 2011 and has stabilized between 1,000-2,000 calls per year in the US.
In humans, cardiovascular effects account for approximately 40% of adverse responses to
synthetic cannabinoids. The most frequently reported being tachycardia (50%) and

hypertension (20%). To test our hypothesis, Sprague Dawley rats were fitted with
chronic indwelling arterial and venous catheters to record blood pressure and heart rate.
Conscious rats were given intravenous injections of vehicle (20% cyclodextrin) then
incremental doses of the synthetic cannabinoid, WIN 55, 212-2 (25, 50, 100 ug/kg + 0.2
ml saline flush). We observed that injection of WIN resulted in rapid onset dose
dependent increases in blood pressure and heart rate that peaked at approximately 18+/-6
mm Hg and 90+/-15 bpm. We also observed that interruption of autonomic function via
ganglion blockade abolished the pressor effect of WIN. Lastly, we also used
immunohistochemistry to assess the role of the PVN in the response to WIN.
Collectively, the data are consistent with the view that synthetic cannabinoids, such as
WIN, increase blood pressure and heart rate via autonomic mechanisms that may be
controlled by the brain.

Key words: Blood Pressure, Heart Rate, Synthetic Cannabinoids, Neuronal Activation,
Paraventricular Nucleus, Amygdala, Autonomic Function
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I.

INTRODUCTION

Cardiovascular Disease Statistics

Cardiovascular diseases: including coronary heart disease, heart failure, stroke,
and hypertension, make up the number one major cause of death in the United States,
affecting 440, 460 males, and 418, 665 females per year (Virani et al., 2021). Cancer,
accidents, chronic lower respiratory disease, Alzheimer’s disease, and diabetes all cause
significantly fewer deaths in comparison (Figure 1). Between the ages of 20-39, 29.8% of
males, and 17.2% of females have some form of cardiovascular disease. At the middle
age bracket, 40-59 years old, over 50% of both males and females have some form of
cardiovascular disease (Virani et al., 2021, pp. e340-e342). As of 2017, there are over
600 thousand deaths attributed to cardiovascular diseases (Virani et al., 2021).

Figure 1. Chart taken from: (Virani et al., 2021, p. e342)
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Figure 2. Chart taken from: (Virani et al., 2021, p. e340)

Hypertension, or dysregulation of blood pressure, is an underlying causative
factor that promotes all of these cardiovascular diseases. Hypertension affects 47.3% of
adults in the United States. While approximately 11% of individuals die due to high
blood pressure, dysregulation of blood pressure is a contributing factor to other diseases
such as coronary artery disease, heart failure, kidney disease, and stroke that also have a
substantial mortality risk. For example, coronary heart disease is the primary cause of
death (42.1%) in the United States (Virani et al., 2021). About every 39 seconds,
someone in the United States has a heart attack. Hypertension is highly prevalent.
Globally, 1.13 billion people suffer from hypertension, 26% of the world’s population.
About 75% of those individuals’ live-in low-income countries (Organization, 2021). Less
than 1 out of 5 people who are diagnosed with hypertension have it controlled, high
systolic BP is the number one risk factor for years of life lost, globally in 2019 (Virani et
2

al., 2021). Since cardiovascular disease is so prevalent, we know that dysregulation of
blood pressure is an important factor in these diseases, factors that increase blood
pressure can have deleterious effects. We are interested in the cardiovascular response to
synthetic cannabinoids.
Synthetic Cannabinoids (Nomenclature/History)
Synthetic Cannabinoids, commonly called “synthetic marijuana” are considered
“designer drugs”, as they are created in a lab and act on the same receptors as THC in
marijuana, however, they bind to those receptors more strongly than THC, produce much
stronger and different effects, and do not show up on a standard drug test. Synthetic
cannabinoids are part of a group of drugs called novel psychoactive substances (NPS).
Non classical synthetic cannabinoids have no medical benefit at present and have a high
potential for abuse. Consumers can buy synthetic cannabinoids in convenience stores,
from individual drug dealers, or online as incense or natural herbal products. They are
sold under a number of brand names, including K2, Spice, and others. Cannabinoids is a
generic name that encompasses both naturally occurring cannabis (marijuana) delta 9
tetrahydrocannabinol, but also synthetic cannabinoids, which can be either classical, with
a structure similar to THC such as dronabinol and nabilone, which are cannabis related,
or the chemically derived “non-classical” synthetic cannabinoids which have a wide
variety of chemical structures, as they are entirely derived chemically and synthesized in
labs, and while they interact with the same systems in the body, they have very different
effects.
The endocannabinoid system is involved in controlling many different processes
in the body: cognitive processing, behavior, memory, appetite, pain, motor functioning,
3

immune functioning, gastrointestinal functionality, nervous system, and cardiovascular
health (Le Boisselier, Alexandre, Lelong-Boulouard, & Debruyne, 2017). There are three
identified cannabinoid receptor ligands. Endocannabinoids (anandamide), naturally
occurring cannabinoids-phytocannabinoids (delta-9-tetrahydrocannabinol, THC) and then
synthetic cannabinoids.

Figure 3. Table taken from: (Waugh et al., 2016)

Figure 3 shows a variety of adverse effects to 3 different types of synthetic
cannabinoids. One of the things I found striking was the fact that people take it for its
psychological effects, but adverse psychological responses only account for about 30% of
the effects, and the cardiovascular adverse responses are far more prevalent than any of
the other effects.
The first synthetic cannabinoids were created for pharmacological research
purposes to study the endocannabinoid system. Researchers found a way to separate the
THC from the plant to use for therapeutic medicinal treatments. In the 1960s,
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neuroscience research transitioned to searching for analgesic and anti-inflammatory
properties of cannabinoid receptor agonists (Lindsay & White, 2012). A majority of SCs
previously synthesized for research purposes were named after the scientist or
corporation that was involved in their synthesis. Pfizer, in 1970, created their own nonclassical cannabinoid, called the CP series, after Charles Pfizer to be utilized for
recreational purposes. In 1995, JWH compounds contained in SCs are named after John
W. Huffman, the Clemson University professor that synthesized it to study its
pharmaceutical effects on the brain (Brents & Prather, 2014) Whereas the AM
compounds are named after a renowned scientist known as Alexandros Makriyannis of
Northeastern University. Furthermore, HU compounds are affiliated to Hebrew
University, created by chemist, Raphael Mechoulam based in Jerusalem, basing HU’s
compound on the structure of THC (Heath, Burroughs, Thompson, & Tecklenburg,
2012). WIN was developed by the research company, Sterling-Winthrop through their
research on pravadoline by conformationally restraining aminoalkylindole analogs,
however, they dropped their research when they discovered WIN was cannabimetic
(Wiley, Marusich, Huffman, Balster, & Thomas, 2011). The classification of SCs for
recreational use was intended to help advertise and market products containing SC. For
instance, AKB-48 denotes the title of a South Korean girl rock band, while XLR-11 was
associated with the first USA-created liquid fuel rocket used by aircrafts. Currently, a
significant percentage of synthetic cannabinoids are given names that derive from their
innate structural compounds, that is, their core, tail name, linker, and associated groups.
However, using the term ‘synthetic marijuana’ to refer to products with synthetic
cannabinoids is debatable and a mistake according to Lewis Nelson, a renowned
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toxicologist in the United States (Ibrahim, Al-Saffar, & Wannenburg, 2014). Nelson
argues that products that contain synthetic cannabinoids are highly variable and
significantly more potent than marijuana, and as long as marijuana is considered a
criminalized drug and not regulated, synthetic cannabinoids, like “spice” and “K2” will
be rampantly available as ‘legal marijuana’ on the market, causing toxic exposures and
clinical consequences (Lapoint et al., 2011; Takematsu et al., 2014). Thus, given that the
term ‘synthetic’ does not denote any known plant, using the phrase synthetic cannabinoid
seems suitable. Synthetic cannabinoids are known by many street names such as K2,
Bombay Blue, and Black Mamba. Fanatics of products containing synthetic cannabinoids
in Spanish nations like Chile, refer to these products as ‘cripy’. In convenience stores and
smoke shops, products with synthetic cannabinoids are referred to as “herbal incense” or
“herbal smoking blends,” with colorful packaging, often labelled as incense or potpourri
often labeled with “not for human consumption, keep out of reach of children” (Zawilska
& Wojcieszak, 2014).
Epidemiology
A good deal of epidemiological data indicates that synthetic cannabinoids have a
history of substantial use and impact on health. From the findings, it was determined that
the drug is highly abused in the U.S. Military and Navy, and for civilians, the abuse is
common among adolescents. Synthetic cannabinoids are a diverse group of compounds
designed to mimic cannabis. While not as frequent as cannabis, their use is still quite
widespread. In 2011, 30 Airmen at an Air Force Base in Oklahoma, were discharged for
spice use. In October of the same year, 64 Sailors were busted for spice use aboard the
carrier, while, one month later, 28 more Sailors were caught on a different carrier. Spice
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use led to the expulsion of 16 men from the Naval Academy in 2011, followed by 14
Coast Guard Academy cadets in January 2012. Between 2011-2012, over 150 personnel
were apprehended for synthetic cannabinoid use in five separate incidents in different
military branches which shows the extent of the problem among the disciplined forces
(White, 2017).
Synthetic cannabinoid use is also highly prevalent in the general public. Kelley et
al., 2013 conducted a field-based study in New York City nightclubs in 2012, finding that
8.2% of 1749 adults with a mean age of 26.4, 55% of those being male, reported using
synthetic cannabinoids in the past year (Kelly et al., 2013).Whereas, in (Winstock et al.,
2011), a 2011 study on synthetic cannabinoid prevalence in the UK, 12.6% of 2700
adults reported using a synthetic cannabinoid in the past year. According to NIH, in 2012,
11% of American high school seniors had used synthetic cannabinoids in the past year
the majority being white males from urban locations (Gunderson, Haughey, Ait-Daoud,
Joshi, & Hart, 2014). In this study, the researchers also found that the proportion of
adolescent males who engaged in synthetic cannabinoid use was 70%. In 2011, 28, 531
emergency room visits, were linked to synthetic cannabinoid use, out of those, 78% were
between the ages of 12-29. In a worldwide survey of nearly 15,000 participants, 17%
reported synthetic cannabinoid use (Singh et al., 2018). Synthetic cannabinoid use is
associated with serious consequences. In Mississippi from April through May of 2015
approximately 1200 emergency room visits, and 17 deaths were attributed synthetic
cannabinoids (White, 2017). In 2015, the American Association of Poison Centers
identified 3500 calls related to synthetic cannabinoid use, a dramatic 299% increase from
just 6 months prior in 2014 (LT George Loeffler, 2012). The increase was immense and
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reveals the problem related to the illegal and unprescribed use of the substance. In 2016,
there were 130 emergency department visits due to synthetic cannabinoid use in New
York City in a single week in July 2016 (White, 2017). According to a study done by
Gloria Martz, between 2014 and 2016, 49.8% of 429 adolescents between the ages of 1317 were admitted to a Children’s Recovery Center in Oklahoma for synthetic cannabinoid
use. 22.4% of these children reported being daily SC users. Martz, in this same study,
discussed that young individuals are at an increased risk for using synthetic cannabinoid
products, as they are relatively inexpensive, easily available, known to produce higher
subjective effects, and difficult to detect on drug tests (Martz, Tankersley, Mekala, &
Motiwala, 2018). In summary, the current epidemiological data indicate that synthetic
cannabinoids are used relatively extensively. There is also a substantial body of data
showing that these substances can have a substantial impact on health.

Figure 4. Data derived from: (Roehler, Hoots, & Vivolo-Kantor, 2020)
8

Figure 4 shows the regional disparity as a trend over time on the proportion of ER
visits related to Synthetic Cannabinoid exposure. Note the regional differences with a
rather stable national trend (the green line) from 2016- 2019. On the West (orange line),
you can see the biggest decline in exposure, however, in the Midwest (the black line)
there is a recent upwards trajectory in exposure.
Effects of Synthetic Cannabinoids in Humans
While synthetic cannabinoids interact with the same endogenous system as
cannabis, their effects are quite different and poorly understood. As seen in Figure 3,
synthetic cannabinoids adversely affect many physiological processes including
gastrointestinal (7.4-13.8% of cases), psychiatric (26.2-29.6%), neurological (18.544.4%) and the most commonly presenting affect is cardiovascular (40.9-44.4%). Serious
adverse cardiovascular effects have presented following both acute and chronic synthetic
cannabinoid use within case reports and clinical studies, resulting in stroke, arrythmias,
cardiomyopathy, myocardial infarction, and cardiac arrest (Pacher, Steffens, Haskó,
Schindler, & Kunos, 2018).In addition to psychological effects that trigger their use, in
humans these substances may cause substantial cardiovascular morbidity including,
increased heart rate and blood pressure which may contribute to deadly effects such as
heart attacks (White, 2017). It seems that the synthetic cannabinoids may activate the
autonomic nervous system, however, how this happens is not yet understood.
Unfortunately, there remains a lot of controversy surrounding how synthetic
cannabinoids affect the cardiovascular system.
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Figure 5. Data compiled from: (Cohen & Weinstein, 2018; Davidson et al., 2017;
Hermanns-Clausen et al., 2016; Jouanjus, Raymond, Lapeyre-Mestre, & Wolff,
2017; White, 2017; Wolff & Jouanjus, 2017; Zaurova, Hoffman, Vlahov, & Manini,
2016)

Figure 5 shows data taken from multiple case studies, regarding the distribution of
acute cardiovascular adverse events in patients using synthetic cannabinoids. the most
predominant effects are related to increases in heart rate, blood pressure and cardiac
arrhythmia. Patients have also presented with angina, which is indicative of disturbances
in cardiac electrical activity and coronary ischemia, respectively.
Cardiovascular Concerns of Excessive Uses of Synthetic Cannabinoids
Researchers have suspected the excessive use of products containing synthetic
cannabinoids for over five decades have resulted in adverse cardiovascular effects.
However, the last decade has experienced a steady increase in reported frequencies of
cardiovascular-related complications. A recent systematic review has concluded that
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there is a positive correlation between excessive use of products containing synthetic
cannabinoids and cardiovascular complications among patients in many hospitals across
the United States (Hermanns-Clausen et al., 2016). To put this into perspective, the
United Kingdom National Poisons Information Service has recorded that between 40-45
percent of all synthetic cannabinoid-linked incidents are of a cardiovascular nature
among youths and individuals in their early adult ages between 2006 and 2010 (Waugh et
al., 2016). Moreover, the prevalence of cardiovascular-related difficulties grew from
1.1% during 2006, to about 3.6% during 2010, whereas the death rate linked to those
complications reached 25% by the end of 2010 (Heath et al., 2012). Synthetic
Cannabinoid users who display these complications are often young males and,
importantly, have no underlying or genetic link for cardiovascular conditions. Common
cardiovascular difficulties of products containing synthetic cannabinoids range from mild
to severe depending on the type of complication. A variety of cardiovascular related
complications have been reported.
Cerebrovascular Disease
Excessive use of products with synthetic cannabinoids leads to the early
development of cerebrovascular disease among individuals in their early 20s, and patients
undergoing cancer treatment procedures. Patients with cardiovascular conditions
showcase symptoms such as neurological impairment and ischemic stroke as the most
common adverse impact as a result of using products containing synthetic cannabinoids
(Singh et al., 2018). Furthermore, a study conducted among a segment of an Australian
population demonstrated that individuals aged between 18 and 44 years suffered from
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ischemic events due to excessive use of products containing synthetic cannabinoids
(Jouanjus et al., 2017; Wolff & Jouanjus, 2017).
Chronic use and smoking of synthetic cannabinoids trigger cerebrovascular events
that impact an individual’s cardiovascular condition. Some of the mechanisms that are
linked to probable cerebrovascular dangers such as direct vasculo-toxic impacts,
modifications in hemodynamics, and atrial fibrillation (Lindsay & White, 2012; White,
2017). Also, temporary exposure to smoke produced by synthetic cannabinoid can trigger
endothelial dysfunction among patients (Singh et al., 2018; Von Der Haar et al., 2016). A
population review in US-based hospitals reveals that people with habitual smoking of
products containing synthetic cannabinoids experience a three-fold increase in the
possibility of developing intense cerebrovascular events (Hermanns-Clausen et al., 2016).
Also, a case study series by the American Heart Association demonstrated that
individuals with ischemic stroke are in danger of suffering a persistent stroke when they
start re-using products containing synthetic cannabinoids (DeFilippis et al., 2020; Khan,
Hanif, & Wilson, 2018; Wolff & Jouanjus, 2017). The male population in the United
States is more at risk to suffer from cerebrovascular disease than women and the fact that
males more commonly are the ones who smoke synthetic cannabinoids is concerning.
Arrhythmias
Incessant usage of products with high concentrations of synthetic cannabinoids
leads to severe cases of arrhythmias and a wide variation of electrical impacts that
deteriorates an individual’s cardiovascular condition. These conditions include atrial
fibrillation, asystole, and supraventricular tachycardia that intensifies an individual’s
CVD situation (Al Fawaz et al., 2019). Additionally, high dosages of synthetic
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cannabinoids caused increases in catecholamines, and the stimulation of cardiac betaadrenergic receptors may heighten the likelihood of a patient developing arrhythmias
(Ozturk, Yetkin, & Ozturk, 2019). Atrial fibrillation is the most common form of
arrhythmias among patients who use products containing synthetic cannabinoids (Pacher
et al., 2018; White, 2017).
The incessant use of synthetic cannabinoids triggers huge fluctuations in cardiac
rhythms. The rhythm variations include sinus tachycardia, ectopic atrial, and ventricular
fibrillation that often leads to sudden cardiac death among patients who are consistent
users. Cardiac tachyarrhythmias are due to excessive use of synthetic cannabinoids
causing the introduction of a hyperadrenergic state (Ozturk et al., 2018; Ozturk et al.,
2019; White, 2017). Further, a recent electrophysiology review to investigate the effects
of excessive use of synthetic cannabinoid compounds reveals the prevalence of inducible
and untimely ventricular contractions. Similarly, myocardial ischemia that occurs due to
microvascular spasm in response to synthetic cannabinoid use may lead to severe
dizziness, syncope, cardiac arrest, and eventually an abrupt cardiac death (Cohen &
Weinstein, 2018).
Cannabis Arteritis
Cannabis vasculopathy is indistinguishable from thrombo-angiitis obliterans,
however, it presents at an earlier age in those who consume both synthetic cannabinoids
and tobacco (Ibrahim et al., 2014). Additionally, subacute and advanced ischemia for
upper and lower limits impacted by arteritis may result in severe difficulties such as
tissue necrosis with deteriorating effects when an individual uses synthetic cannabinoids
(Ibrahim et al., 2014). Additional vascular difficulties of nonstop use of synthetic
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cannabinoid products are migratory thrombophlebitis, renal artery segmentation, and
vasculopathy concerning the occlusion of the primary retinal veins (Singh et al., 2018).
Clinical Implications
The two German investigators who smoked “Spice Diamond” experienced the
acute effects due to smoking which included change in opinions and thinking, and dry
mouth (White, 2017). According to their study, the use of synthetic cannabinoids causes
tachycardia, impairment of mood and perception, anxiety, loss of concentration, paranoia,
and then post use, extreme fatigue. The most common adverse events associated with the
use of synthetic cannabinoids include agitation, drowsiness, vomiting, and other extreme
effects which easily lead to death. Males who are over the age of 30 years were more
likely to die and experience serious symptoms as compared to the female counterparts
(Zaurova et al., 2016). The most common cardiovascular symptom associated with the
use of synthetic cannabinoids include tachycardia with a heart rate of 90-170 beats every
minute. In addition, at least a third of the patients exhibited hypertension (Zaurova et al.,
2016). Hypokalemia, muscle pain, and acute psychosis were also some of the major
symptoms that developed and last for several days. The typical psychotic and
neurological effects include the drowsiness, paranoia, and euphoria which developed with
continuous and use of synthetic cannabinoids. A study conducted between patients with
exposure to synthetic cannabinoids and other patients who had smoked traditional
marijuana revealed modified and altered mental status and cardiotoxicity of the
individuals who had used the synthetic cannabinoids (Zaurova et al., 2016).
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Effects of Synthetic Cannabinoids in Rats
Short term administration of these agents to anesthetized animals result in an
overall decrease in blood pressure (Malinowska, Baranowska-Kuczko, & Schlicker,
2012; Malinowska, Toczek, Pedzinska-Betiuk, & Schlicker, 2019; O'Sullivan, 2015). In
contrast, research in conscious animals is more limited, but these agents appear to cause
an increase in blood pressure (Ho & Gardiner, 2009; S.M. Gardiner, 2001; Schindler,
Gramling, Justinova, Thorndike, & Baumann, 2017). Schindler (Schindler et al., 2017)
saw increases in blood pressure with a series of synthetic cannabinoids. Gardiner (S.M.
Gardiner, 2001) responses show dose dependent increases in blood pressure. However,
both of these studies showed a decrease in heart rate. (Niederhoffer & Szabo, 1999)
reported a decrease in blood pressure with WIN 55, 212-2 in conscious rabbits.
Therefore, there remains considerable controversy regarding the effects of synthetic
cannabinoids in cardiovascular function in animals, which limits understanding of the
mechanisms involved. Several pharmacologic effects are associated with synthetic
cannabinoids which was determined to induce anxiety in animals. For instance, in rats, it
contributes to higher serum corticosterone concentrations that directly refer to the aspect
of being responsive to stress (White, 2017). (Niederhoffer & Szabo, 1999) however, in
their study they found no evidence for vasodilation in response to WIN 55, 212-2.
Evidence for PVN in Cardiovascular Control
The paraventricular nucleus of the hypothalamus (PVN) amongst many other
functions, is known to regulate the autonomic nervous system by controlling the
sympathetic outflow to the heart and the blood vessels. Due to its critical role in
regulating sympathetic tone, dysregulation in sympathetic activity directly correlates to

15

dysregulation of the heart, and in some cases, heart failure. Pre-autonomic neurons of the
PVN become disinhibited and lead to increased sympathetic activity via glutamate and
angiotensin II (Pyner, 2014). The PVN plays a critical role in regulating blood volume
via the mechanoreceptors in the heart. An increase in blood volume stimulates increases
in heart rate, renal vasodilation via vasopressin neurotransmission, increases in urine
output, and sodium loss (Dampney, Michelini, Li, & Pan, 2018). It is also known that the
PVN is critical in chronic stress responses, psychological stress, such as conditioned fear,
as well as continuous increases in sympathetic nerve activity (Dampney et al., 2018). It is
known that in spontaneously hypertensive rats, the PVN pre-sympathetic neuronal
excitement and sympathetic outflow is significantly increased in comparison to
normotensive rats, such as Sprague Dawley rats. PVN pre-sympathetic neurons are
critical to increases in sympathetic vasomotor activation that causes increases in blood
pressure and hypertension (Dampney et al., 2018). Some work suggests that cannabinoid
receptors are expressed in the PVN (Grzeda et al., 2015; Ozturk et al., 2019). Thus, the
PVN may be involved in the cardiovascular responses to synthetic cannabinoids.
cFos as a Neuronal Marker
cFos is a gene that is activated through sensory stimulation, as it encodes for the
Fos transcription factor. The Fos protein is produced in the cytoplasm, then travels to the
nucleus where it combines with other proteins to create heterodimeric transcription
complexes in order to regulate transcription of other genes (Kovacs, 2008). Neuronal Fos
signal activation occurs where the animal is exposed to a novel stimulus for a 90-minute
period of time. Immunostaining, which is the application of antibodies that work against
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the desired protein, in this case, cFos protein as a neuronal marker, can be observed
(Chung, 2015).
Summary of Rationale
The use of synthetic cannabinoids is prevalent and increasing in some countries.
Epidemiological data indicate that use of synthetic cannabinoids is associated with
significant cardiovascular mortality. Data in animals is mixed with some data showing
decreases in blood pressure and heart rate whereas, other data shows increase in blood
pressure and heart rate. A major difference occurs between anesthetized and conscious
animals, suggesting involvement of the brain. CB receptors are extensively distributed in
the brain and are known to be found in the PVN.
Statement of Hypothesis
We hypothesize that the PVN is a site in the brain that synthetic cannabinoids act
on to cause increased blood pressure by activating the sympathetic autonomic nervous
system, thereby, wiping out the response by inhibiting neurotransmission. Looking at the
big picture, this project aims to identify the role of the PVN in the abuse of synthetic
cannabinoids and how they are associated with cardiovascular adverse effects, so if we
understand their mechanisms of action, we can figure out effective treatments.
Specific Aims
1) Determine the blood pressure and heart rate responses to a synthetic cannabinoid,
WIN 55, 212-2, in conscious rats.
2) Determine the role of the autonomic nervous system in these responses.
3) Determine if the hypothalamic paraventricular nucleus is involved in the response
to synthetic cannabinoids.
17

II.

MATERIALS AND METHODS

Animals
Male Sprague Dawley rats (300-400 grams) from ENVIGO or the Animal
Resource Center (ARC) 60-90 days old were used. The animals were housed in the ARC
two per cage, in a room with many other rats. The room is set on a specific light/dark
cycle, where the lights turn on at 6 am and turn off at 6 pm. The protocols used were
approved by the Institutional Animal Care and Use Committee (IACUC) and observed
NIH guidelines.
Surgical Interventions
Male Sprague Dawley rats (300-400 grams) were randomly selected and placed in
an anesthesia chamber connect to a gas anesthetic (isoflurane) vaporizer. Isoflurane (5%)
with an oxygen flow rate of 3 L/min was used to induce anesthesia. Once the animal had
lost the righting reflex, the isoflurane was adjusted to 2-3% to maintain anesthesia. The
rat was shaved at the surgical locations, the femoral area and the nape of the neck. Each
surgical area was wiped with iodine scrub (x2) and 70% isopropyl alcohol ending with a
wipe of regular iodine to disinfect the surgical sites. The rat was then transferred to a
water jacket heating pad (set at 45 degrees C), taped down in the dorsal recumbent
position, artificial tears were placed on the eyes, and the rat placed back in the nose cone
with the isoflurane anesthesia this time at the 2.5 level. Anesthesia was adjusted based on
need as judged by the respiratory rate or reaction to pinch. The rat’s tail was labeled with
indelible marker for permanent identification. The surgical area surrounding the rat was
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wiped down with 70% isopropyl alcohol. A surgical pack that had been autoclaved at a
sterilization temperature of 270 degrees for 20 minutes, with a 15-minute drying time was
placed next to the surgical area. The rats were covered with a piece of Press and Seal
wrap (Glad Wrap) to serve as a sterile surgical drape. The surface was scrubbed with
70% isopropyl alcohol. Sterile gloves and a surgical mask were put on, and the surgical
pack was opened.
The rats were treated with Buprenorphine SR (1.2 mg/mL/kg) to provide
analgesia. A fourth of an inch incision was made through the skin at the femoral area
vertically towards the midline using scissors. Then, blunt dissection using forceps was
used to separate tissues until the femoral artery and vein were revealed. The vessels were
isolated from each other using blunt dissection with forceps, and a 3-0 black silk nonabsorbable suture was placed around each vessel at both the proximal and distal ends.
During this process, the area was infiltrated with 2% lidocaine to provide local anesthesia
and relax the vessels for catheter insertion. The sutures were first used to occlude the
flow of the vessels during catheter insertion. Then a small cut was made on the vessels
using micro-Vanna spring scissors to introduce the catheters into the vessels.
Polyethylene Tubing (PE-50) connected to a syringe containing heparinized saline (25
U/ml) for the venous catheter tubing. The arterial catheter consisted of Tygon microbore
tubing (0.020”) glued together with a 1” long piece of micro-renathane MRE-025 for the
intravascular portion. The catheter was glued together days prior to the surgery using
E6000 to bind it together. The micro-renathane provided a non-thrombotic surface to
prolong catheter patency during chronic implantation. The venous and arterial catheters
were soaked for an hour in iodine and then for an hour in 70% isopropyl alcohol and
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flushed with heparin saline prior to implantation. The catheters were then introduced into
the vessels about 1”, tied in place, then tunneled subcutaneously to the back of the neck
using a trochar. The femoral area was sutured closed with 4-0 violet braided, polyglycolic
acid, absorbable suture followed by 2-4 stables and vet bond. The area at the back of the
neck was sutured around the catheters with 3-0 black silk non absorbable suture,
wrapping the catheters around 6 times, and sealed with vet bond to help hold the catheters
during chronic implantation. The catheters were trimmed to about ¾” sticking out
between the ears, flushed with heparin saline, and plugged. For plugs, we used a blunted
and crimped 22 gage hypodermic needle about ¼” long, injected with E6000 glue which
was allowed to dry a few days prior to surgery to bond and seal. The wounds were
covered with a topical antibiotic ointment (bacitracin). The rats were returned to their
home cage. After the rats regained consciousness and were mobile, they were returned to
the animal quarters to recover.
Protocol
The animals were then allowed 3-5 days of recovery, then trained to the recording
area for 2-3 days. The animals were checked on daily, to assess for general condition,
mobility, leg functioning, and weight. On the training days, the rats were brought to the
recording room so they could acclimate to the environment. On the training days, the
rat’s arterial and venous catheters were flushed with heparin saline to ensure there were
no clots. On the experimental days, the arterial line was connected to a pressure
transducer connected to the BioPac recording system where arterial pressure and heart
rate were recorded continuously.
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The rationale for the doses of WIN were taken from the literature (S.M. Gardiner,
2001). The cyclodextrin vehicle is made up from a 20% weight to volume ratio with
sterile water and then vortexed until into solution. Initially, we attempted 50, 100, and
300 g/kg doses, but the 300 g/kg had severe adverse behavioral effects, so we switched
to doses of 25, 50, and 100 g/kg. The WIN was made up by weighing out between 400700 micrograms, and then mixed with it 20% Cyclodextrin (vehicle) to make the stock
solution of 100 g/kg. To go into solution, the 100 g/kg dose of WIN was put in the
sonicator for about 20 minutes, then placed in a beaker of water on a hot plate at level 8
for 10 minutes, vortexed, then placed back on the sonicator for 20 minutes. This
procedure was repeated until the drug went into solution. To make the subsequent doses,
we used serial dilutions. The 50 g/kg was made from diluting part of the stock solution
with the vehicle by a one-to-one ratio, then the 25 g/kg was made from diluting part of
the 50 g/kg with the vehicle by a one-to-one ratio.
A baseline recording (about 30 minutes to an hour) was obtained, until the rats
exhibited a calm, stable blood pressure and heart rate. The rats then received an
intravenous injection of 0.2 mL 20% cyclodextrin vehicle followed by 0.2 mL saline
flush. Responses to the vehicle injection were recorded for approximately 20 minutes.
After this, the rats received injections of 0.2 mL of a synthetic cannabinoid, WIN 55,
212-2, at the doses of 25, 50, and 100 g/kg, followed by a 0.2 mL saline flush
monitoring for between 30 minutes to an hour in-between each dose. Blood pressure and
heart rate were monitored for approximately 20 minutes after each injection. In all cases,
blood pressure and heart rate were allowed to return to baseline prior to the next
injection.
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Ganglion Block Procedure
Some of the rats were subjected to ganglionic blockade. After getting a successful
response from the 3 doses of WIN and allowing blood pressure and heart rate to return to
baseline, the rats received an intravenous injection of a ganglion blocker. Ganglionic
blockade was used to assess the role of the autonomic nervous system in the responses to
WIN injection. Ganglionic blockade was achieved by intravenous injection of
chlorisondamine iodide at a dose of 10 mg/kg/0.1ml. The chlorisondamine was made by
weighing out an amount of drug based on the animal’s weight and sufficient to make up
about 0.3-0.4 milliliters of solution (extra to account for amounts lost in the needle hub
and line). Chlorisondamine iodide is relatively insoluble in aqueous solutions. It was
dissolved by adding the drug powder to the appropriate amount of sterile water in a
sterile test tube. The solution was then gently heated on a water bath in 1-minute
increments with vortexing at each step until the drug went into solution. Once in
solution, the chlorisondamine solution was loaded into a 1 ml syringe to deliver the drug
to the rat. 0.1 mL of solution was delivered intravenously followed by a 0.2 ml saline
flush. After this injection, the rats were monitored until blood pressure and heart rate
became stable (roughly 10 minutes) then given an injection of 0.2 mL 100 microgram per
kilogram WIN 55, 212-2 followed by a 0.2 mL saline flush. The rats were then monitored
for 30 minutes to observe the effect of WIN after ganglion blockade.
Brain Collection Procedure
Immunohistochemistry was used to assess the brain involvement in the responses
to WIN. The following procedure was used to collect the brain for this purpose. The
animal was injected with either 0.2 mL WIN (100 µg/kg) or 20% cyclodextrin vehicle
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followed by a 0.2 mL saline flush through the venous catheter then monitored for 90
minutes. The rats were then anesthetized deeply with urethane chloralose (800 mg/kg: 80
mg/kg). After waiting for 15 minutes, deep anesthesia was confirmed by tail pinch.
Then, the animal was placed in a collection tray in the fume hood. A cut was made at the
xiphoid process, snipping up on both sides of the diaphragm until the heart was exposed.
The right atrium was then snipped to release blood, then 40-50 mL of heparin saline was
injected into the left ventricle to flush the vascular system of blood. This was followed
by 40-50 mL of 4% paraformaldehyde for perfusion fixation of the brain. A big scissor
was then used to separate the head from the body, the skin on the top of the head was
peeled back to reveal the skull then a rongeur is used to carefully chip away the skull like
an eggshell to collect the brain. The brain was then placed in a solution of 4%
paraformaldehyde for 24 hours for post fixation. After which the brain was transferred
for long-term storage to a 20% sucrose solution to cryoprotect the brain in preparation for
cryosectioning.
Cryosectioning Procedure
The cryostat was set to -20 degrees and to cut sections at 30 microns. The frontal
lobe and the occipital lobe of the brain were then cut off using a razor blade to block the
brain for mounting on the sectioning pedestals. The brain was then mounted onto the
pedestal using Tissue-Tek O.C.T compound and then placed into a bucket of crushed dry
ice for a few minutes to ensure rapid, complete and uniform freezing. Then, the mounted
brain was placed into the chuck of the cryostat. 30-micron sections were taken, and the
chuck adjusted until an even section was obtained. Sections were discarded until the
optic chiasm and 3rd ventricle became visible. The sections were then collected, three per
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slide, from approximately bregma -1.30 to -2.30 mm using anatomical markers (e.g.,
optic chiasm) as depicted in the atlas of Paxinos and Watson. The sections are mounted to
the slides by carefully placing them on the slide and then placing a warm finger
underneath so that it would heat up and bind to the slide. The section to slide arrangement
are as follows: the first slide: sections 1, 4, and 7, second slide: 2, 5, and 8. third slide: 3,
6, and 9; and so forth. This staggered order on successive slides was used to allow close
proximity of sections destined for immunohistochemical and histochemical staining.
Immunohistochemistry Procedure
First, a hydrophobic barrier with a Vector laboratories ImmEdgeTM Pen was
applied around each section on each slide. Then, the sections were subjected to a heatinduced antigen retrieval protocol as follows. 100 mL of citrate buffer with a pH of 6 was
boiled for five minutes in a beaker. Then, the tissue slides were placed in a six-well
plastic slide box and the citrate buffer was poured over the top of the slides, and then
boiled in the microwave again for seven minutes. After boiling, the plastic slide box was
immersed in an ice bath for one hour to cool the sections.
After one hour in the ice bath, the following IHC protocol was performed. The
slides were washed 5 times each with 1% phosphate buffered saline containing 1% (v/v)
Tween detergent (PBS-T). The 1% PBS-T is made up of a phosphate buffered saline
tablet (Sigma P4417) in 200 mL of ultra-pure water and 2 mL Tween 20. Then, the slides
were placed back into the plastic slide box for application of antibody solutions. The
primary antibodies were made in a solution of 10% goat serum in 1% PBS-T. The 10%
goat serum in 1% PBS-T is made up of 1 mL Goat Serum in 9 mL 1% PBS-T. The
primary antibody used was an Abcam rabbit polyclonal to cFos (ab190289) (1mg/ml).
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For application to the sections, a 1:100 dilution was used by taking 1-part Abcam
primaries to 99 parts 10% goat serum in 1% PBS-T (10 µL Abcam and 990 µL 10% Goat
Serum in 1% PBST). For staining, 10 µL of the cFos primary antibody solution was
placed on the first section and the third section of each slide. The middle section on each
slide was used as a primary antibody negative control section. This section was treated
with a negative control of 10 µL 10% goat serum in 1% PBS-T which did not contain the
primary antibody. Then, the plastic slide box was placed in the fridge on the rocker at 4
degrees Celsius for 24-hours. After 24 to 48 hours, the slides were thoroughly washed
five times with 1% PBS-T prior to application of the secondary antibody. The secondary
antibodies were applied to each of the three sections on the slides. The secondary
antibodies are made up from a donkey or goat anti-rabbit highly cross-absorbed
secondary antibody, Alexa Fluor Pluss 488 (2 mg/mL) Invitrogen (donkey: A32766,
goat: A32731). 10 µL of the anti-donkey or anti-goat secondary antibody was diluted in
1990 µL of 10% goat serum in PBST. 10 µLs was then applied to each section on the
slide. The slides were then left in a covered box for two hours at room temperature for
incubation and to protect from light since the fluorescent antibodies are subject to
photobleaching. After two hours incubating in the secondary antibodies, the slides are
thoroughly washed five times with 1% PBS-T and then a coverslip mounting medium
containing 4′,6-diamidino-2-phenylindole, DAPI (to visualize nuclei) was placed on each
of the sections on the slide, and then a dust-free coverslip was placed over the top. The
slides were stored in the covered opaque box in the fridge at 4 degrees Celsius for 40
minutes. After 40 minutes, the sections were then used for fluorescent microscopy.
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Cresyl Violet Staining Procedure
Cresyl violet stains the DNA and RNA nucleic acids in the brain in order to detect
the shapes of the structures in the brain. Slides adjacent to the ones we ran for the
immunohistochemistry procedure were then taken for cresyl violet staining, to confirm
the location of the PVN. The cresyl violet stock solution is made up of 0.2 grams cresyl
violet-acetate with 150 mL distilled water, then mixed with a stir bar for 20 minutes. The
buffer solution (pH 3.5) was made from 282 mL of 0.1 M acetic acid (6 mL concentrated
acetic acid per 1000 mL distilled water) with 18 mL of 0.1 M sodium acetate (13.6 grams
in 1000 mL distilled water). Then, 30 mL of cresyl violet stock solution with 300 mL of
buffer were mixed for 30 minutes. First, the slides were placed in Xylene for 5 minutes,
then 95% isopropyl alcohol for 3 minutes, then 70% isopropyl alcohol for 3 minutes, then
deionized distilled water for 3 minutes, then cresyl violet for 8 minutes, distilled water for
3 minutes, 70% isopropyl alcohol for 3 minutes, 95% alcohol for 1 minute, then one dip
of 100% isopropyl alcohol, then HemoD for 5 minutes, then Citrisol for up to 24 hours.
Then, the slides were cover slipped with a histological mounting medium and left
overnight to dry before observing under the microscope.
Fluorescent Microscopy
A Leica DMLB microscope with Leica Application Suite X software was used for
the fluorescent microscopy procedure. An emission wavelength of 488 was used to
visualize cFos under the microscope and the DAPI channel was used to get emission at
wavelength of 461 fluorescence for DAPI. Images were taken for the WIN injected
brain’s as well as the vehicle injected brains at 10x, 20x, and 40x of both 488 and DAPI
for the PVN area with and without primary antibodies, the Amygdala area with and
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without primary antibodies. At least 24 images per slide were collected. The cFos
staining with the DAPI staining at each magnification level for each location were then
overlayed to identify if the perceived cFos staining was within the nuclei. Then, the
cresyl violet slides were observed through light/bright field under the microscope at 5x
magnification and images were taken at both the PVN and Amygdala for each slide.

III.

DATA ANALYSIS

Blood Pressure and Heart Rate Data
The blood pressure and heart rate data were analyzed from each tracing by
measuring the baseline blood pressure and heart rate before each injection, then the blood
pressure and heart rate for one-minute durations every five minutes post injection to
obtain the time course of each response. The peak heart rate and blood pressure to each
of the doses of WIN injection were also collected for a one-minute duration. Once
acquiring these data were compiled into Excel spreadsheets and transferred to an analysis
package (GraphPad Prism) for analysis. Data was checked for outliers using Grubb’s
test. One blood pressure data point was removed since it tested out to be an outlier. Data
that did not meet criteria for parametric analysis were log transformed prior to analysis.
Image J Analysis of Immunofluorescence Images

TIFF images of the overlay for cFos and DAPI staining were imported into NIH
Image J. These color images were then separated into their red (nonexistent), green
(cFos) and blue (DAPI) component channels. Background subtraction was performed on
each channel. The threshold feature of Image J was then used to despeckle the images.
An area encompassing the region of interest (PVN or Amygdala) was defined using the
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polygon tool on Image J. The bounded area was then analyzed using the analyze particle
function from the analysis menu. This produced an output that included the number of
particles (counts). Matched areas were used to analyze the green (cFos) and blue (DAPI)
channels. The particle counts from each analysis was entered into an Excel spreadsheet.
cFos staining was expressed as a proportion of overall cell number in the selected area as
reflected by the DAPI particle counts (% cFos staining = (cFos particle count/DAPI
particle count) x 100). Staining was evaluated on the sections with and without primary
antibody, and in rats treated with WIN or with vehicle.
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IV.

RESULTS

Effect of WIN 55, 212-2 on blood pressure and heart rate in conscious rats.
Raw tracings for blood pressure and heart rate are shown in figure 6. Briefly,
cyclodextrin vehicle did not appear to affect blood pressure or heart rate whereas WIN

Figure 6. This figure shows real time tracings for arterial blood pressure (top tracing in each
panel) and heart rate (lower tracing in each panel) before and during injection of
cyclodextrin vehicle (top left) and WIN 55, 212-2 in increasing doses of 25, 50 and 100 µg/kg.
Vehicle injection did not markedly affect blood pressure or heart rate. Injection of WIN
increased both blood pressure and heart rate.

injection increased both blood pressure and heart rate. Summary data are presented in
figures 7 and 8. Baseline blood pressure and heart rate averaged approximately 122 4
mm Hg and 356 11 bpm prior to the injection of the cyclodextrin vehicle. Injection of
cyclodextrin vehicle caused changes in blood pressure 0.2 1 mm Hg and heart rate -1 2
bpm that were not significantly different from baseline. In contrast, intravenous injection
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of WIN produced markedly different effects. These data are illustrated in figures 6
(MAP) and 7 (HR). At the lowest dose of 25 µg/kg, blood pressure increased by 7 2
mm Hg while heart rate increased by 30 7 bpm. At the middle dose of 50 µg/kg, these
responses were 163 mm Hg and 5813 bpm. At our highest dose of 100 µg/kg, we
observed an increase of 18 2 mm Hg in blood pressure, and 74 10 bpm in heart rate.
These responses were significantly greater than that caused by vehicle injection.
Therefore, intravenous injection of WIN was associated with dose dependent increases in
blood pressure and heart rate.

Figure 7. This figure shows the changes in mean arterial pressure obtained in
conscious rats (n=10-11) injected with vehicle (0) or incremental doses of a
synthetic cannabinoid, WIN 55, 212-2 at doses of 25, 50 and 100 µg/kg.
ANOVA followed by Dunnett’s Test. * Indicates significant difference from
vehicle control p<0.05
30

Figure 8. This figure shows the changes in heart rate obtained in conscious rats
(n=10-11) injected with vehicle (0) or incremental doses of a synthetic cannabinoid,
WIN 55, 212-2 at doses of 25, 50 and 100 µg/kg. ANOVA followed by Dunnett’s Test.
* Indicates significant difference from vehicle control p<0.05

We also measured the MAP and HR responses for 20 minutes after injection to
establish a time course. The data are shown in figures 9 (MAP) and 10 (HR). As shown
in figure 9, the blood pressure response reached its highest point within the first 5 minutes
after injection and then declined thereafter.

However, blood pressure remained

significantly elevated compared to vehicle injection up to the 15-minute mark. At the
lowest dose, blood pressure was no longer significantly higher than vehicle injection at 20
minutes post injection. As might be expected, higher doses had longer durations and the
blood pressure responses to WIN remained significantly above those for vehicle even after
20 minutes.
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A somewhat similar pattern was observed in terms of heart rate. WIN injection
produced very rapid onset increases in heart rate that appeared to peak at around 5 minutes
post injection. Somewhat different from blood pressure however, heart rate did not rapidly
decrease over time and were in fact maintained for up to 20 minutes (figure 10).

Figure 9. This figure shows the time course of the changes in blood pressure obtained
in conscious rats (n=10) injected with vehicle or incremental doses of a synthetic
cannabinoid, WIN 55, 212-2 at doses of 25, 50 and 100 ug/kg. Repeated measures
ANOVA followed by Student Newman Keul test. * p<0.05 vehicle vs 25 ug/kg, Ф
p<0.05 vehicle vs 50 ug/kg, Ƭ p<0.05 vehicle vs 100 ug/kg
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Figure 10. This figure shows the time course of the changes in heart rate
obtained in conscious rats (n=10) injected with vehicle or incremental doses of a
synthetic cannabinoid, WIN 55, 212-2 at doses of 25, 50 and 100 µg/kg.
Repeated measures ANOVA followed by Student Newman Keul test. * p<0.05
vehicle vs 25 µg/kg, Ф p<0.05 vehicle vs 50 µg/kg, Ƭ p<0.05 vehicle vs 100
µg/kg

Effect of Ganglion Blockade
The cardiovascular responses to synthetic cannabinoids may involve an
autonomic nervous system component. We used pharmacological ganglion blockade to
assess the role of the autonomic nervous system. Ganglion blockers work by blocking
the transmission at the sympathetic and parasympathetic ganglia in the autonomic
nervous system. Administration of the ganglion blocking agent, chlorisondamine,
reduced both blood pressure (1205 to 804 mm Hg) and heart rate (38112 to 34517
bpm). Figure 10 shows compares the MAP and HR responses to WIN 100 µg/kg obtained
before and after ganglionic. This data shows that Synthetic Cannabinoid, WIN, acts by
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increasing sympathetic outflow. Pre-ganglionic blockade, we observed a change in mean
arterial blood pressure of 17 2 and change in heart rate of 63 9. Post ganglionic
blockade, we observed a MAP response of 1 2 mm Hg and a HR response of -13 5
bpm. Therefore, ganglionic blockade abolished the response to WIN.

Figure 11. This figure shows the effect of autonomic blockade on blood pressure and
heart rate obtained in conscious rats (n=6) injected with synthetic cannabinoid, WIN
55, 212-2 at a dose 100 µg/kg. Paired t-test. * Indicates significant difference from
vehicle control p<0.05

Immunohistochemistry
We used cFos immunohistochemistry as an approach to detect neuronal activation
in response to drug injection. Each immunohistochemistry run included a section in
which no primary antibody was included. This section served as an antibody negative
control as illustrated in figure 12. Very little punctate green (cFos) staining was
observed in these sections indicating little to no non-specific binding of the fluorescent
secondary antibody.
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Figure 12. This figure shows fluorescent immunohistochemistry images for cFos (green)
and DAPI staining in a section where the primary antibody to cFos was omitted. These
sections served as antibody negative controls. From the top left shows 488 emissions,
then DAPI staining (top right), overlay of 488 and DAPI low power (bottom left) and high
power (bottom middle). The lower right shows a cresyl violet image to identify location.
There is virtually no green punctate staining indicating that there was very little
nonspecific binding of the secondary antibody. Scale bars are shown in each figure. 3rd V
= third ventricle, PVN = paraventricular nucleus

Two animals received vehicle injection prior to brain collection and served as
vehicle controls for immunohistochemistry. The results from these two rats were
variable as illustrated in figure 13. In one case there was some positive cFos staining
observed as depicted in figure 12. This staining was relatively sparsely distributed but
appeared to be localized primarily along the lower ventricular margin of the PVN. In the
other vehicle injected rat, no staining was observed in the PVN.
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Figure 13. This figure shows fluorescent immunohistochemistry images for cFos (green) and
DAPI (blue) staining in a section where the rat was injected with cyclodextrin vehicle. From
the top left shows 488 emissions, then DAPI staining (top right), overlay of 488 and DAPI low
power (bottom left) and high power (bottom middle). The lower right shows a cresyl violet
image to identify location. Some positive cFos staining was observed with as indicated by
the arrows. Scale bars are shown in each figure. 3rd V = third ventricle, PVN = paraventricular
nucleus

WIN injection was associated with an increase in cFos staining. An
example of this staining is shown in figure 14. Punctate green staining was
observed in the region of the PVN in discrete cells. DAPI overlay was consistent
with the idea that this staining occurred in the nucleus, consistent with cFos
staining. The cresyl violet (Nissl stain) image shows that this section was taken in
the early-mid PVN region.
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Figure 14. Composite immunohistochemistry images of the PVN from a WIN injected rat, at
10x using Leica DMLB microscope with Leica Application Suite X software. Top left: cFos
staining observed at emission wavelength of 488. Note the punctate green staining absent in
the antibody negative control sections in figure 12. Top right: DAPI staining observed at
emission wavelength of 461. Bottom left: Overlay of cFos and DAPI at 10x magnification.
Bottom middle is overlay at 20x. Scale bars are shown in the figures. Bottom right: Cresyl
Violet Staining observed through light field at 5x.

Summary data for PVN cFos staining is shown in figure 15. These data
are expressed as the proportion of cFos positive cells to DAPI positive cell counts.
Virtually no staining consistent with cFos staining was observed in the antibody
negative control sections (0.60.4%). Vehicle injection was associated with a
small but observable increase in the proportion of cells exhibiting cFos staining in
the PVN region (31%). WIN injection also elicited an increase in the proportion
of cells staining positive for cFos in the PVN region (92%). The WIN induced
increase in cFos staining was significantly greater than that observed for either
antibody negative control or vehicle control.
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Figure 15. This figure shows the counts of cFos staining in percent DAPI at the PVN with no
primary (n=5), animals treated with vehicle only (n=2), and animals treated with WIN 55,
212-2 (n=5). ANOVA followed by Student Newman Keul test. * Indicates significant
difference from vehicle control p<0.05

Although not part of our overall hypothesis, we also observed increases in cFos
staining a region ventral and lateral to the PVN. This area corresponds to an area
described as the medial amygdaloid nucleus in the atlas of Paxinos and Watson
(figure 16).
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Figure 16. Image of the coronal section from the atlas of Paxinos and Watson shown a
coronal section through the brain region where we detected positive cFos staining
follow injection of WIN 55, 212-2. Arrow shows location of medial amygdaloid nucleus.

Figure 17 shows images for staining observed in an antibody negative control
section in the region of the MeAD. Very little punctate green (cFos) staining was
observed in these sections indicating little to no non-specific binding of the
fluorescent secondary antibody.
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Figure 17. This figure shows fluorescent immunohistochemistry images for cFos (green) and
DAPI (blue) staining in a section where the primary antibody to cFos was omitted. These
sections served as antibody negative controls. From the top left shows 488 emissions, then
DAPI staining (top right), overlay of 488 and DAPI low power (bottom left) and high power
(bottom middle). The lower right shows a cresyl violet image to identify location. There is
virtually no green punctate staining indicating that there was very little non-specific binding
of the secondary antibody. Scale bars are shown in each figure. MeAD = Medial Amygdaloid
Nucleus

As observed with the PVN, vehicle injection appeared to increase positive
cFos staining in the MeAD region as well as shown in figure 18. cFos staining was
relatively sparsely distributed through this region.

Nevertheless, high power

examining did show nice overlay of the green and blue staining consistent with
positive cFos staining.
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Figure 18. This figure shows fluorescent immunohistochemistry images for cFos (green)
and DAPI (blue) staining in a section where the rat was injected with cyclodextrin vehicle.
From the top left shows 488 emissions, then DAPI staining (top right), overlay of 488 and
DAPI low power (bottom left) and high power (bottom middle). The lower right shows a
cresyl violet image to identify location. Some positive cFos staining was observed with as
indicated by the arrows. Scale bars are shown in each figure. MeAD= Medial Amygdaloid
Nucleus

WIN injection was also associated with an increase in positive cFos staining in the
MeAD region. An example of this staining is shown in figure 19. Punctate green
staining was observed in discrete cells. DAPI overlay was consistent with the idea that
this staining occurred in the nucleus, consistent with cFos staining. Visually this
staining appeared to be denser than that produced by vehicle injection. The cresyl
violet (Nissl stain) image shows that this section was taken in the Medial Amygdaloid
Nucleus.
Summary data for Amygdala cFos staining is shown in figure 20. These data are
expressed as the proportion of cFos positive cells to DAPI positive cell counts.
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Virtually no staining consistent with cFos staining was observed in the antibody
negative control sections

Figure 19. Composite immunohistochemistry images of Amygdala observed in a rat that
received WIN 55, 212-2 injection. Magnification at 10x using Leica DMLB microscope with
Leica Application Suite X software. Top left: cFos staining observed at emission
wavelength of 488. Note the punctate green staining absent in the antibody negative
control sections in figure 17. Top right: DAPI staining observed at emission wavelength
of 461. Bottom left: Overlay of cFos and DAPI at 10x magnification. Bottom middle is
overlay at 20x. Scale bars are shown in the figures. Bottom right: Cresyl Violet Staining
observed through light field at 5x.

(0.360.17%). Vehicle injection was associated with a small but observable
increase in the proportion of cells exhibiting cFos staining in the Amygdala region
(4.51.8%). WIN injection also elicited an increase in the proportion of cells
staining positive for cFos in the amygdala region (225%). The WIN induced
increase in cFos staining was significantly greater than that observed for either
antibody negative control.
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Figure 20. This figure shows the counts of cFos staining in percent DAPI at the
Amygdala with no primary (n=5), animals treated with vehicle only (n=2), and
animals treated with WIN 55, 212-2 (n=5). ANOVA followed by Student Newman
Keul test. * Indicates significant difference from vehicle control p<0.05
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V.

DISCUSSION

In our study of the hemodynamic responses to WIN 55, 212-2, we saw dose
dependent increases in blood pressure and heart rate. At our highest dose of WIN 55,
212-2, 100 µg/kg, we observed an increase of 18±2 mm Hg in blood pressure, and 74 ±10
bpm in heart rate. (Schindler et al., 2017) used several other synthetic cannabinoids:
JWH-018 AM2201, XLR-11, CP55, 940. They saw dose dependent increases in blood
pressure with peak changes of about 15 mm Hg. Our findings using WIN 55, 212-2 are
consistent with this, as we saw changes in blood pressure of about 18 mm Hg. A pressor
response appears to be a general feature of synthetic cannabinoids, as all of them increase
blood pressure in conscious rats. As an example, (Schindler et al., 2017) found that CP55,
940, JWH-018, and AM2201, and XLR-11 produced a hypertensive effect. The literature
is consistent with our findings on synthetic cannabinoids in blood pressure. In contrast,
(Schindler et al., 2017) found no change in heart rate, where we observed significant dose
dependent increases in heart rate. It is difficult to reconcile these opposing findings.
However, (Schindler et al., 2017) used subcutaneous injection, where we used direct
intravenous injection, which may have allowed greater access of the drugs to the brain.
Also, in contrast to our findings, (Niederhoffer & Szabo, 1999) reported that
intravenous injection of WIN 55, 212-2 acts to decrease blood pressure and heart rate in
conscious rabbits. They ascribed this to peripheral sympathetic inhibition. These
differences are difficult to explain but may be due to the difference in species used. In
addition, (Malinowska et al., 2012) summarized the effects of various synthetic
cannabinoids on blood pressure and heart rate as seen in the literature, which
overwhelmingly suggests that there is a difference in response that is seen upon
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administration of a synthetic cannabinoid in conscious animals versus anesthetized
animals. In conscious animals, synthetic cannabinoids are widely reported to produce
increases in blood pressure and heart rate, whereas in anesthetized animals, decreases are
seen. As an example, (Kristy D. Lake, 1997) reported dose dependent decreases in mean
arterial pressure and heart rate, but their work used urethane chloralose anesthetized rats.
(Malinowska et al., 2012) confirmed the marked distinction between conscious and
anesthetized responses. As referenced in figure 5, this is important, since humans use the
drug while they are conscious, and the human data shows tachycardia and hypertension.
The data for conscious responses is more relevant to what is seen in humans. Our data is
consistent with the responses seen in humans.
The hypertensive effects of synthetic cannabinoids are an opposing response than
what seen in cannabis. Although there have been some conflicting reports, the bulk of the
evidence suggests that THC seems to lower blood pressure and produce bradycardia in
both conscious and anesthetized animals, as well as in humans (Sultan, Millar,
O'Sullivan, & England, 2018). This reinforces the view that while they presumably act on
the same system, synthetic cannabinoids produce markedly different responses than
synthetic cannabinoids.
(López-Dyck et al., 2017; Spiller et al., 2019) studied the expression of CB1 and
CB2 receptors in the vasculature using two synthetic cannabinoids, ACPA, and JWH133. They looked at what the effects of these synthetic cannabinoids did on each receptor
in terms of vascular tone. They found that if you activate CB1 or CB2 receptors, you get
vascular dilation, which lowers blood pressure and heart rate (López-Dyck et al., 2017).
However, we saw increases in blood pressure and heart rate, our findings suggest that the
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increased blood pressure and heart rate are occurring due to a mechanism within the
brain.
There are cannabinoid receptors located all throughout the different regions of the
brain. (Spiller et al., 2019) found that CB1 and CB2 receptors are expressed both in the
vasculature, as well as in the reward and aversion centers of the brain, including the
ventral tagmental area and the nucleus acumbens. The CB1 receptors in the PVN have
been shown to affect cardiovascular responses, as Grezda (Grzeda et al., 2015) saw that
upon microinjection of a CB1 receptor antagonist into the PVN, then injection of CP55,
940 into the PVN, stimulation of CB2 receptors in the PVN caused increases in blood
pressure and heart rate. In addition, lesions of the PVN abolished their responses to
intravenous injection of CP55, 940.
Prior work has shown that autonomic blockade attenuates the responses to
synthetic cannabinoids, (S.M. Gardiner, 2001) and (Schindler et al., 2017). We injected
chlorisondamine iodide prior to injection of our highest dose of WIN, 100 µg/kg to block
autonomic functioning to determine if the sympathetic nervous system is involved in the
mechanism of increased blood pressure and heart rate seen when injecting WIN 55, 2122. Our findings show that injection of ganglionic blocker prior to injection of WIN 55,
212-2 completely blocks the effect of WIN. The literature supports our findings that the
autonomic nervous system mediates the cardiovascular effects of WIN 55, 212-2.
Gardiner used pentolinium for a ganglion blocker and found that it antagonized the
pressor effect of WIN (S.M. Gardiner, 2001). (Schindler et al., 2017) found that
pretreatment of hexamethonium as a ganglion blocker, antagonizes the increased blood
pressure and heart rate responses seen using two other synthetic cannabinoids. Our work
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is consistent with that found in the literature. Under our conditions, with our animals,
using WIN 55, 212-2, we have determined that it appears the increases in blood pressure
and heart rate caused by WIN is mediated through the brain via the autonomic nervous
system. Possibly, the reason others have reported seeing vasodilator effects, is because of
the study done by (Niederhoffer & Szabo, 1999) that shows that it actually blocks the
release of norepinephrine, but maybe that is overcome by the central nervous system, so
when we block the nerves at the ganglia, there is no norepinephrine to block to prevent
release, so that is why we did not see that effect in our responses.
The current literature in combination with our findings suggest that synthetic
cannabinoids cause a sympathetic pressor effect via the brain, when administered within
conscious animals. When injected prior to WIN 55, 212-2; the chlorisondamine iodide
(10 mg/kg/0.1 mL) blocks the effect of WIN 55, 212-2 on the rest of the system,
suggesting that the autonomic nervous system is involved. The PVN is involved in
autonomic control (Dampney et al., 2018; Pyner, 2014). Injection of synthetic
cannabinoids into the PVN increases blood pressure and heart rate (Grzeda et al., 2015).
We used cFos immunohistochemistry, to assess brain involvement, focusing on
the PVN. In our study, even though we did see cFos staining within the vehicle,
specifically within the PVN and amygdala (figure 18). WIN produced a much stronger
increase in cFos staining (figure 15, figure 20) than the vehicle in both the PVN and
Amygdala. Any effect of the vehicle seen in the PVN, and Amygdala are likely due to
handling or stress. The PVN is involved in autonomic control, blood pressure and heart
rate responses (Dampney et al., 2018), and has CB receptors (Grzeda et al., 2015), so it is
logical to conclude that the PVN is part of the circuitry involved in the blood pressure
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and heart rate response, as we saw. Stimulation of the amygdala causes many
physiological responses including negative emotions, anxiety, stress, increases in
sympathetic nervous system activation, and increases in blood pressure and heart rate
(Kraynak, Marsland, & Gianaros, 2018). Some reports have suggested that CB receptors
are found in the amygdala (Katona, 2001). So, it seems reasonable to suggest that the
amygdala is involved in the responses that we saw. Since cFos is a marker of neuronal
activation, our results suggest that the PVN and the Amygdala are both involved in the
mechanism of the hypertensive and tachycardic cardiovascular responses we saw in
response to WIN 55, 212-2.

VI.

CONCLUSION

Our data is consistent with the view that synthetic cannabinoids increase blood
pressure and heart rate via the autonomic nervous system to adversely affect the
cardiovascular system. The immunohistochemistry showed cFos activation within the
PVN and the Amygdala, which suggests that the brain is involved in the cardiovascular
effect of synthetic cannabinoid, WIN 55, 212-2. In the human data, increases in heart rate
are the most frequent response seen, followed by increases in blood pressure being
second, as seen in figure 5. Cardiovascular adverse effects are the most common response
to synthetic cannabinoids, as seen in figure 4. Human causes of death upon consumption
of synthetic cannabinoids are as a result of the severe cardiovascular responses. More
research to explore the underlying mechanisms may lead to better treatment options for
the adverse effects of synthetic cannabinoids.
Further research is needed to prove the linkage between these processes. Going
forward, we would like to investigate the causal link between the cardiovascular
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responses to WIN and PVN. We would like to block the amygdala as well as the PVN to
see if the cardiovascular responses go away. Blocking the CB1 and then the CB2
receptors in the PVN to see if it changes response. Another option would be to block the
CB1 and CB2 receptors in the amygdala to see if that changes the response.
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VIII.

APPENDIX

Oral Presentation, “Synthetic Cannabinoids Impact on Cardiovascular Health,”
University of South Dakota Idea Fest 2021, April 7-8, 2021.
IPS/MSPS Scientific Sessions Outstanding Undergraduate Oral Presentation

2020

Synchronous Oral Presentation, “Impact of Synthetic Cannabinoids on Cardiovascular
Health,” Midlands Society of Physiological Sciences, October 30-31, 2020.
Oral Presentation, “Synthetic Cannabinoids and Cardiovascular Health,” Society for
Neuroscience, Faculty for Undergraduate Neuroscience (FUN) Neuroscience
Undergraduate Research Virtual Symposium (NURVS) Presentation FF-7, October 25,
2020.
Virtual Presentation, “Impact of Synthetic Cannabinoids on Cardiovascular Health,”
USD Alumni Association and Foundation’s Heritage Club, August 28, 2020.
U Discover Scholar

May 26, 2020-August 3, 2020

Grant awarded to fund research project evaluating impact of synthetic cannabinoids on
cardiovascular health. PI: Dr. Doug Martin, Sanford School of Medicine’s Basic
Biomedical Sciences
Poster Presentation, “Mechanisms of Cardiovascular Responses to Synthetic
Cannabinoids,” Society for Neuroscience, FUN Poster Session and Social, October 20,
2019.
Poster Presentation, “Mechanisms of Cardiovascular Responses to Synthetic
Cannabinoids,” CBBRe Neurobehavioral Research Symposium, August 15-16, 2019.
SPURA Scholar

May 20, 2019-August 16, 2019

Undergraduate research in addiction fellowship grant awarded to fund research project
evaluating mechanisms of cardiovascular responses to synthetic cannabinoids. PI: Dr.
Doug Martin, Sanford School of Medicine’s Basic Biomedical Sciences
Poster Presentation Co-Author, The Cardiac Sympathetic Afferent Reflex and its
Relationship to the Paraventricular Nucleus, Heart, and Veins, 3rd Annual Eastern South
Dakota Research Symposium, June 12, 2019.
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